0001209191-17-053004.txt : 20170915 0001209191-17-053004.hdr.sgml : 20170915 20170915164300 ACCESSION NUMBER: 0001209191-17-053004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170913 FILED AS OF DATE: 20170915 DATE AS OF CHANGE: 20170915 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nielsen Ulrik B. CENTRAL INDEX KEY: 0001531962 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35409 FILM NUMBER: 171088373 MAIL ADDRESS: STREET 1: MERRIMACK PHARMACEUTICALS, INC. STREET 2: ONE KENDALL SQUARE, SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MERRIMACK PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001274792 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-441-1000 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-09-13 0 0001274792 MERRIMACK PHARMACEUTICALS INC MACK 0001531962 Nielsen Ulrik B. C/O MERRIMACK PHARMACEUTICALS, INC. ONE KENDALL SQUARE, SUITE B7201 CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2017-09-14 4 M 0 100 13.20 A 22781 D Common Stock 2017-09-14 4 S 0 100 14.20 D 22681 D Common Stock 2017-09-15 4 M 0 7133 13.20 A 29814 D Common Stock 2017-09-15 4 M 0 663 13.20 A 30477 D Common Stock 2017-09-15 4 S 0 7796 14.23 D 22681 D Stock Option (right to buy) 13.99 2017-09-13 4 A 0 7500 0.00 A 2027-09-12 Common Stock 7500 7500 D Stock Option (right to buy) 13.20 2017-09-14 4 M 0 100 0.00 D 2017-10-04 Common Stock 100 7133 D Stock Option (right to buy) 13.20 2017-09-15 4 M 0 7133 0.00 D 2017-10-04 Common Stock 7133 0 D Stock Option (right to buy) 13.20 2017-09-15 4 M 0 663 0.00 D 2017-10-04 Common Stock 663 0 D This option is fully vested. This option was previously reported as covering 3,378 shares of common stock at an exercise price of $2.59 per share, but was adjusted to reflect both the special cash dividend that was payable on May 26, 2017 and the reverse stock split that became effective for trading purposes on September 6, 2017. /s/ Brian J. Kickham, attorney-in-fact 2017-09-15